产品说明书

Methocarbamol

Print
Chemical Structure| 532-03-6 同义名 : AHR 85;NSC 170960
CAS号 : 532-03-6
货号 : A160451
分子式 : C11H15NO5
纯度 : 98%
分子量 : 241.24
MDL号 : MFCD00057662
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(435.25 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 4 mg/mL(16.58 mM),配合低频超声助溶

动物实验配方:
生物活性
描述 Methocarbamol is a commonly used, centrally acting muscle relaxant and has not been linked to instances of liver injury[3]. Methocarbamol is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. Absorption and elimination of methocarbamol is similar between normal subjects and patients undergoing maintenance haemodialysis[4]. Patients who were treated with methocarbamol showed a significant decrease in the frequency and duration of cramps. Also, the pain score improved significantly. Methocarbamol seems to be a promising safe and well-tolerated medication, and plays a role in the treatment of muscle cramps in patients with liver cirrhosis[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00770497 Inflammation ... 展开 >>Hypertension 收起 << Phase 2 Completed - Germany ... 展开 >> Deggingen, Baden-Württemberg, Germany Rottweil, Baden-Württemberg, Germany Spaichingen, Baden-Württemberg, Germany Weilersbach, Bayern, Germany Hannover, Niedersachsen, Germany Essen, Nordrhein-Westfalen, Germany Köln, Nordrhein-Westfalen, Germany Werne, Nordrhein-Westfalen, Germany Mainz, Rheinland-Pfalz, Germany Schauenburg, Rheinland-Pfalz, Germany Dresden, Sachsen, Germany Blankenhain, Thüringen, Germany Berlin, Germany 收起 <<
NCT02707094 Chronic Low Back Pain Not Applicable Completed - United States, Texas ... 展开 >> Brooke Army Medical Center Fort Sam Houston, Texas, United States, 78234 收起 <<
NCT02669875 Liver Cirrhosis ... 展开 >> Hypertension, Portal 收起 << Phase 2 Completed - United Kingdom ... 展开 >> Liver Unit, Royal Infirmary of Edinburgh Edinburgh, United Kingdom, EH164TJ 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.15mL

0.83mL

0.41mL

20.73mL

4.15mL

2.07mL

41.45mL

8.29mL

4.15mL

参考文献

[1]Rumpler MJ, Colahan P, Sams RA. The pharmacokinetics of methocarbamol and guaifenesin after single intravenous and multiple-dose oral administration of methocarbamol in the horse. J Vet Pharmacol Ther. 2014 Feb;37(1):25-34.

[2]Kuo K, Odunayo A. Adjunctive therapy with intravenous lipid emulsion and methocarbamol for permethrin toxicity in 2 cats. J Vet Emerg Crit Care (San Antonio). 2013 Jul-Aug;23(4):436-41.

[3]Methocarbamol. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; January 30, 2017

[4]Sica DA, Comstock TJ, Davis J, et al. Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-194

[5]Abd-Elsalam S, Arafa M, Elkadeem M, et al. Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019;31(4):499-502